Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines

Kristan B. Burrows, Wendy L. Nixdorf, Bryan Yamamoto

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

These studies examined, in vivo, the effect of local intrastriatal perfusion of methamphetamine (MA) on dopamine (DA) and glutamate release in relation to changes in striatal DA and serotonin (5-HT) content measured 1 week after treatment. Interactions between the inhibition of energy metabolism and the direct perfusion of MA on long-term decreases in DA and 5- HT content also were investigated. MA (100 μM), the succinate dehydrogenase inhibitor malonate, or the combination of MA and malonate was reverse- dialyzed into the striatum for 8 h. The continuous local perfusion of MA alone increased DA release by 30-fold, similar to that seen after systemic administration, but did not increase glutamate or body temperature, and did not deplete neurotransmitter content. Malonate perfusion increased both DA and glutamate overflow, and dose dependently decreased DA content. 5-HT content was not as affected by malonate perfusions (200 mM malonate depleted DA by 66% and 5-HT by 40%). When MA was coperfused with 200 mM malonate, DA content was reduced by 80% and to a greater extent compared with malonate alone. Coperfusion of MA and 200 mM malonate did not enhance 5-HT loss. Overall, the present findings provide evidence that energy metabolism plays an important role in MA toxicity and that striatal dopaminergic terminals are more vulnerable than 5-HT terminals to damage after metabolic stress.

Original languageEnglish (US)
Pages (from-to)853-860
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume292
Issue number3
StatePublished - Mar 2000
Externally publishedYes

Fingerprint

Corpus Striatum
Methamphetamine
Dopamine
Serotonin
Perfusion
Glutamic Acid
Energy Metabolism
Physiological Stress
Succinate Dehydrogenase
malonic acid
Body Temperature
Neurotransmitter Agents

ASJC Scopus subject areas

  • Pharmacology

Cite this

Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines. / Burrows, Kristan B.; Nixdorf, Wendy L.; Yamamoto, Bryan.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 292, No. 3, 03.2000, p. 853-860.

Research output: Contribution to journalArticle

@article{4ab8f130df2a419b9b5be2635d4a65eb,
title = "Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines",
abstract = "These studies examined, in vivo, the effect of local intrastriatal perfusion of methamphetamine (MA) on dopamine (DA) and glutamate release in relation to changes in striatal DA and serotonin (5-HT) content measured 1 week after treatment. Interactions between the inhibition of energy metabolism and the direct perfusion of MA on long-term decreases in DA and 5- HT content also were investigated. MA (100 μM), the succinate dehydrogenase inhibitor malonate, or the combination of MA and malonate was reverse- dialyzed into the striatum for 8 h. The continuous local perfusion of MA alone increased DA release by 30-fold, similar to that seen after systemic administration, but did not increase glutamate or body temperature, and did not deplete neurotransmitter content. Malonate perfusion increased both DA and glutamate overflow, and dose dependently decreased DA content. 5-HT content was not as affected by malonate perfusions (200 mM malonate depleted DA by 66{\%} and 5-HT by 40{\%}). When MA was coperfused with 200 mM malonate, DA content was reduced by 80{\%} and to a greater extent compared with malonate alone. Coperfusion of MA and 200 mM malonate did not enhance 5-HT loss. Overall, the present findings provide evidence that energy metabolism plays an important role in MA toxicity and that striatal dopaminergic terminals are more vulnerable than 5-HT terminals to damage after metabolic stress.",
author = "Burrows, {Kristan B.} and Nixdorf, {Wendy L.} and Bryan Yamamoto",
year = "2000",
month = "3",
language = "English (US)",
volume = "292",
pages = "853--860",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines

AU - Burrows, Kristan B.

AU - Nixdorf, Wendy L.

AU - Yamamoto, Bryan

PY - 2000/3

Y1 - 2000/3

N2 - These studies examined, in vivo, the effect of local intrastriatal perfusion of methamphetamine (MA) on dopamine (DA) and glutamate release in relation to changes in striatal DA and serotonin (5-HT) content measured 1 week after treatment. Interactions between the inhibition of energy metabolism and the direct perfusion of MA on long-term decreases in DA and 5- HT content also were investigated. MA (100 μM), the succinate dehydrogenase inhibitor malonate, or the combination of MA and malonate was reverse- dialyzed into the striatum for 8 h. The continuous local perfusion of MA alone increased DA release by 30-fold, similar to that seen after systemic administration, but did not increase glutamate or body temperature, and did not deplete neurotransmitter content. Malonate perfusion increased both DA and glutamate overflow, and dose dependently decreased DA content. 5-HT content was not as affected by malonate perfusions (200 mM malonate depleted DA by 66% and 5-HT by 40%). When MA was coperfused with 200 mM malonate, DA content was reduced by 80% and to a greater extent compared with malonate alone. Coperfusion of MA and 200 mM malonate did not enhance 5-HT loss. Overall, the present findings provide evidence that energy metabolism plays an important role in MA toxicity and that striatal dopaminergic terminals are more vulnerable than 5-HT terminals to damage after metabolic stress.

AB - These studies examined, in vivo, the effect of local intrastriatal perfusion of methamphetamine (MA) on dopamine (DA) and glutamate release in relation to changes in striatal DA and serotonin (5-HT) content measured 1 week after treatment. Interactions between the inhibition of energy metabolism and the direct perfusion of MA on long-term decreases in DA and 5- HT content also were investigated. MA (100 μM), the succinate dehydrogenase inhibitor malonate, or the combination of MA and malonate was reverse- dialyzed into the striatum for 8 h. The continuous local perfusion of MA alone increased DA release by 30-fold, similar to that seen after systemic administration, but did not increase glutamate or body temperature, and did not deplete neurotransmitter content. Malonate perfusion increased both DA and glutamate overflow, and dose dependently decreased DA content. 5-HT content was not as affected by malonate perfusions (200 mM malonate depleted DA by 66% and 5-HT by 40%). When MA was coperfused with 200 mM malonate, DA content was reduced by 80% and to a greater extent compared with malonate alone. Coperfusion of MA and 200 mM malonate did not enhance 5-HT loss. Overall, the present findings provide evidence that energy metabolism plays an important role in MA toxicity and that striatal dopaminergic terminals are more vulnerable than 5-HT terminals to damage after metabolic stress.

UR - http://www.scopus.com/inward/record.url?scp=0034009082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034009082&partnerID=8YFLogxK

M3 - Article

C2 - 10688597

AN - SCOPUS:0034009082

VL - 292

SP - 853

EP - 860

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -